| Budget Amount *help |
¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2015: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2014: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2013: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Outline of Final Research Achievements |
LPXN acts as a signal transducing adaptor protein and plays important roles in cell adhesion and spreading. We discovered a novel fusion gene between ETV6 on 12p13 and LPXN on 11q12.1 in leukemic cells of a patient with relapsed acute myeloid leukemia. ETV6-LPXN did not transform the interleukin-3-dependent 32D myeloid cell line; however, an enhanced proliferative response was observed when these cells were treated with G-CSF without inhibition of granulocytic differentiation. The 32D and human leukemia cell lines each transduced with ETV6-LPXN showed enhanced migration towards the chemokine CXCL12. The immunofluorescence data indicated that ETV6-LPXN oligomerized, because it was detected as discrete spots in the cytoplasm, although LPXN was diffusively distributed throughout the cytoplasm. Our data indicate that ETV6-LPXN is associated with progression of leukemia through modulation of G-CSF and CXCL12/CXCR4, potentially acting within the microenvironment of leukemic cells.
|
